Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by Truist Financial Corp

Truist Financial Corp trimmed its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 15.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 207,819 shares of the company’s stock after selling 36,574 shares during the quarter. Truist Financial Corp’s holdings in Takeda Pharmaceutical were worth $2,966,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC increased its position in Takeda Pharmaceutical by 73.1% during the third quarter. SG Americas Securities LLC now owns 16,043 shares of the company’s stock worth $248,000 after buying an additional 6,775 shares during the period. Cambridge Investment Research Advisors Inc. boosted its stake in Takeda Pharmaceutical by 5.7% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 16,433 shares of the company’s stock worth $254,000 after purchasing an additional 883 shares during the period. Advisor Partners II LLC grew its position in Takeda Pharmaceutical by 19.0% during the 3rd quarter. Advisor Partners II LLC now owns 80,100 shares of the company’s stock worth $1,239,000 after purchasing an additional 12,802 shares during the last quarter. Park Avenue Securities LLC increased its stake in Takeda Pharmaceutical by 37.7% in the third quarter. Park Avenue Securities LLC now owns 37,477 shares of the company’s stock valued at $580,000 after purchasing an additional 10,255 shares during the period. Finally, Sage Rhino Capital LLC boosted its stake in shares of Takeda Pharmaceutical by 7.6% during the third quarter. Sage Rhino Capital LLC now owns 11,751 shares of the company’s stock worth $182,000 after buying an additional 831 shares during the period. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Performance

NYSE TAK opened at $13.28 on Wednesday. Takeda Pharmaceutical Company Limited has a 52-week low of $13.01 and a 52-week high of $17.11. The business’s 50-day moving average price is $13.85 and its 200 day moving average price is $14.10. The company has a quick ratio of 0.55, a current ratio of 1.06 and a debt-to-equity ratio of 0.64. The firm has a market cap of $42.03 billion, a P/E ratio of 20.12, a P/E/G ratio of 3.05 and a beta of 0.56.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.